Biologics in the management of pediatric inflammatory bowel disease: When and what to choose

Figure 3 Comparative safety, relative annual cost (in India) and efficacy profile of various biologics in pediatric inflammatory bowel disease. PIBD: Pediatric inflammatory bowel disease; IFX: Infliximab; ADA: Adalimumab; UST: Ustekinumab; VDZ: Vedolizumab; TOFA: Tofacitinib; CD: Crohn’s disease; UC: Ulcerative colitis; ASUC: Acute severe ulcerative colitis; (1): Response rates to biologics taken from reference[21,25,26,31,34,103]; (2): Response rates to biologics taken from reference[30,31,68]; (3): Response rates to biologics taken from reference[62]; (4): Response rates to biologics taken from reference[36]; (5): Response rates to biologics taken from reference[53,56]; (6): Response rates to biologics taken from reference[51]; (7): Response rates to biologics taken from reference[33]; (8): Response rates to biologics taken from reference[57].